Drug updated on 11/1/2024
| Dosage Form | Injection (intravenous; 1,100 kBq/mL [30 microcurie/mL]) |
| Drug Class | Alpha particle-emitting radioactive therapeutic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- The study notes the potential benefits of radium-223 (Xofigo) in cancer therapy but lacks specific effectiveness outcomes, such as response rates, survival rates, or symptom relief metrics.
- No comparative effectiveness information is available in the study, as it does not include other drugs for relative assessment.
- Effectiveness differences among population types or subgroups are not addressed in the study.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xofigo (radium Ra 223 dichloride) Prescribing Information. | 2019 | Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Where Do We See Alpha Emitters in Clinical Practice? A Radiation Oncology Perspective | 2019 | Journal of Medical Imaging and Radiation Sciences |